Pharmacologic smoking cessation interventions for patients with cardiovascular conditions : a review of the safety and guidelines (eBook, 2012) [WorldCat.org]
skip to content
Pharmacologic smoking cessation interventions for patients with cardiovascular conditions : a review of the safety and guidelines
Checking...

Pharmacologic smoking cessation interventions for patients with cardiovascular conditions : a review of the safety and guidelines

Author: Canadian Agency for Drugs and Technologies in Health.
Publisher: [Ottawa, Ont.] : Canadian Agency for Drugs and Technologies in Health, 2012
Series: Rapid response report.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Cardiovascular disease (CVD) is a collective term referring to a group of diseases affecting the heart and blood vessels including: ischemic heart disease, stroke, peripheral vascular disease, heart failure, rheumatic heart disease, and congenital heart disease. Tobacco smoking is an important modifiable risk factor for cardiovascular events and Canadian and international clinical practice guidelines unanimously  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health.
OCLC Number: 806242521
Notes: "16 May 2012."
Description: 1 online resource (30 pages) : tables, digital file.
Series Title: Rapid response report.
Responsibility: [prepared by Canadian Agency for Drugs and Technologies in Health].
More information:

Abstract:

Cardiovascular disease (CVD) is a collective term referring to a group of diseases affecting the heart and blood vessels including: ischemic heart disease, stroke, peripheral vascular disease, heart failure, rheumatic heart disease, and congenital heart disease. Tobacco smoking is an important modifiable risk factor for cardiovascular events and Canadian and international clinical practice guidelines unanimously recommend smoking cessation for patients with CVD. Strategies for health care professionals who are assisting patients attempting to quit smoking can include counseling and the use of pharmacotherapy. Commonly used pharmacotherapy for smoking cessation includes nicotine replacement therapy (NRT), bupropion hydrochloride (Zyban), and varenicline tartrate (Champix). CADTH has conducted a health technology assessment which evaluated the clinical and cost-effectiveness of pharmacologic-based strategies for smoking cessation. 9 Patients with CVD and smoking-related diseases were a subpopulation of interest in the CADTH review. The report suggested that nicotine gum, nicotine patch, bupropion, and varenicline were efficacious as an aid for smoking cessation compared with placebo for this patient population; however, harms data were not assessed in the review. In addition, Canadian and international regulatory agencies have recently updated the safety information for varenicline to include a warning regarding a potential increase in the risk of cardiovascular events in patents with CVD. The present review was conducted to summarize the available safety evidence for varenicline, bupropion, and NRT in patients with CVD. A search for evidence-based guidelines and recommendations on the use of these agents was also conducted to provide information regarding current practice.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.